In the field of neovascular (wet) AMD, the use of contrast sensitivity function as a more sensitive functional outcome may demonstrate larger treatment effects after therapeutic interventions such as anti-VEGF injections compared to VA, larger difference in the treatment effect of different therapeutic interventions and even treatment effect when VA improvement may have plateaued. The gene discussed is VEGFA; the disease is age-related macular degeneration.